Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing.
Ghilu S, Kurmasheva RT, Houghton PJ. Ghilu S, et al. Among authors: houghton pj. J Clin Med. 2021 Apr 4;10(7):1504. doi: 10.3390/jcm10071504. J Clin Med. 2021. PMID: 33916592 Free PMC article.
With current multimodality treatments, the 5-year event-free survival exceeds 80%, and 70% of patients achieve long-term "cure", hence the overall number of patients eligible for experimental drugs is small. ...
With current multimodality treatments, the 5-year event-free survival exceeds 80%, and 70% of patients achieve long-term "cure", henc …
Challenges and Opportunities for Childhood Cancer Drug Development.
Houghton PJ, Kurmasheva RT. Houghton PJ, et al. Pharmacol Rev. 2019 Oct;71(4):671-697. doi: 10.1124/pr.118.016972. Pharmacol Rev. 2019. PMID: 31558580 Free PMC article. Review.
However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having chronic life-threatening toxicities related to therapy in their fourth or fifth decade of life. ...
However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having …
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.
Jones L, Carol H, Evans K, Richmond J, Houghton PJ, Smith MA, Lock RB. Jones L, et al. Among authors: houghton pj. Leukemia. 2016 Nov;30(11):2133-2141. doi: 10.1038/leu.2016.192. Epub 2016 Jul 15. Leukemia. 2016. PMID: 27416986 Review.
However, certain pediatric ALL subgroups remain relatively intractable to treatment and many patients who relapse face a similarly dismal outcome. Moreover, survivors of pediatric ALL suffer the long-term sequelae of their intensive treatment throughout their lives. ...
However, certain pediatric ALL subgroups remain relatively intractable to treatment and many patients who relapse face a similarly dismal ou …
Identifying novel therapeutic agents using xenograft models of pediatric cancer.
Kurmasheva RT, Houghton PJ. Kurmasheva RT, et al. Among authors: houghton pj. Cancer Chemother Pharmacol. 2016 Aug;78(2):221-32. doi: 10.1007/s00280-016-3042-6. Epub 2016 May 18. Cancer Chemother Pharmacol. 2016. PMID: 27193096 Free PMC article. Review.
However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction and cognitive impairment. ...
However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction …
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.
Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Geier B, et al. Among authors: houghton pj. Front Oncol. 2015 Aug 26;5:193. doi: 10.3389/fonc.2015.00193. eCollection 2015. Front Oncol. 2015. PMID: 26380223 Free PMC article. Review.
However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. ...
However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidi …
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ. Studebaker A, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2015 Oct;62(10):1768-74. doi: 10.1002/pbc.25579. Epub 2015 May 15. Pediatr Blood Cancer. 2015. PMID: 25981859 Free PMC article.
Patients with recurrent low-grade tumors or anaplastic astrocytoma may receive radiation treatment; however, the long-term sequellae from radiation treatment can be severe. As many childhood gliomas are associated with activation of BRAF, we have explored the combination o …
Patients with recurrent low-grade tumors or anaplastic astrocytoma may receive radiation treatment; however, the long-term sequellae …
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC. Taylor AC, et al. Among authors: houghton pj. Med Pediatr Oncol. 2000 Aug;35(2):96-103. doi: 10.1002/1096-911x(200008)35:2<96::aid-mpo2>3.0.co;2-z. Med Pediatr Oncol. 2000. PMID: 10918230
RESULTS: A mutation was detected in only 1 of 20 tumor specimens (5%), whereas the frequency in established RMS cell lines was significantly higher (6/10, 60%). p53 Mutations were more common in cell lines derived from tumors previously exposed to chemotherapy compared to those d …
RESULTS: A mutation was detected in only 1 of 20 tumor specimens (5%), whereas the frequency in established RMS cell lines was significantly …
Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes.
Douglass EC, Valentine M, Rowe ST, Parham DM, Wilimas JA, Sanders JM, Houghton PJ. Douglass EC, et al. Among authors: houghton pj. Genes Chromosomes Cancer. 1990 Sep;2(3):210-6. doi: 10.1002/gcc.2870020308. Genes Chromosomes Cancer. 1990. PMID: 1964081
In a seventh case only normal cells were identified in short-term culture, but a del(13)(q14) appeared after 4 months in culture. ...
In a seventh case only normal cells were identified in short-term culture, but a del(13)(q14) appeared after 4 months in culture. ...